Unknown

Dataset Information

0

Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections.


ABSTRACT: Antibiotic-resistant bacteria are widespread and pose a growing threat to human health. New antibiotics acting by novel mechanisms of action are needed to address this challenge. The bacterial methionyl-tRNA synthetase (MetRS) enzyme is essential for protein synthesis, and the type found in Gram-positive bacteria is substantially different from its counterpart found in the mammalian cytoplasm. Both previously published and new selective inhibitors were shown to be highly active against Gram-positive bacteria with MICs of ?1.3 ?g/ml against Staphylococcus, Enterococcus, and Streptococcus strains. Incorporation of radioactive precursors demonstrated that the mechanism of activity was due to the inhibition of protein synthesis. Little activity against Gram-negative bacteria was observed, consistent with the fact that Gram-negative bacterial species contain a different type of MetRS enzyme. The ratio of the MIC to the minimum bactericidal concentration (MBC) was consistent with a bacteriostatic mechanism. The level of protein binding of the compounds was high (>95%), and this translated to a substantial increase in MICs when the compounds were tested in the presence of serum. Despite this, the compounds were very active when they were tested in a Staphylococcus aureus murine thigh infection model. Compounds 1717 and 2144, given by oral gavage, resulted in 3- to 4-log decreases in the bacterial load compared to that in vehicle-treated mice, which was comparable to the results observed with the comparator drugs, vancomycin and linezolid. In summary, the research describes MetRS inhibitors with oral bioavailability that represent a class of compounds acting by a novel mechanism with excellent potential for clinical development.

SUBMITTER: Faghih O 

PROVIDER: S-EPMC5655057 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections.

Faghih Omeed O   Zhang Zhongsheng Z   Ranade Ranae M RM   Gillespie J Robert JR   Creason Sharon A SA   Huang Wenlin W   Shibata Sayaka S   Barros-Álvarez Ximena X   Verlinde Christophe L M J CLMJ   Hol Wim G J WGJ   Fan Erkang E   Buckner Frederick S FS  

Antimicrobial agents and chemotherapy 20171024 11


Antibiotic-resistant bacteria are widespread and pose a growing threat to human health. New antibiotics acting by novel mechanisms of action are needed to address this challenge. The bacterial methionyl-tRNA synthetase (MetRS) enzyme is essential for protein synthesis, and the type found in Gram-positive bacteria is substantially different from its counterpart found in the mammalian cytoplasm. Both previously published and new selective inhibitors were shown to be highly active against Gram-posi  ...[more]

Similar Datasets

| S-EPMC155832 | biostudies-literature
| S-EPMC3084089 | biostudies-literature
| S-EPMC5120670 | biostudies-literature
| S-EPMC6437504 | biostudies-literature
| S-EPMC4604383 | biostudies-literature
| S-EPMC7103878 | biostudies-literature
2020-12-23 | PXD021527 | Pride
| S-EPMC3480199 | biostudies-literature
| S-EPMC8165550 | biostudies-literature
| S-EPMC8216282 | biostudies-literature